UroGen Pharma (URGN) Fundamental Analysis: Revenue, Earnings & Valuation

3.18 / 10

Netural

Fundamental score is 3.2/10, indicating poor quality. Inventory turnover and cost‑of‑sales ratios are strong, but long‑term debt to working capital and operating‑revenue growth are weak. Overall the fundamentals are neutral to negative.

Analysis Checks(6/10)

Revenue-MV

Value-1.39

Score1/3

Weight17.92%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value21.45

Score1/3

Weight-1.41%

1M Return-0.38%

Inventory turnover ratio

Value0.97

Score3/3

Weight-3.54%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value15.17

Score3/3

Weight6.70%

1M Return1.67%

PB-ROE

Value4.32

Score2/3

Weight33.65%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value1.86

Score1/3

Weight-2.42%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.18%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value21.45

Score1/3

Weight-1.11%

1M Return-0.30%

Cost of sales ratio (%)

Value11.34

Score3/3

Weight1.04%

1M Return0.26%

Asset-MV

Value-0.55

Score2/3

Weight53.36%

1M Return11.12%

Is URGN fundamentally strong?

URGN scores 3.18/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -139.81% net margin, -6.01 P/E ratio, -8.74 P/B ratio, and -7.77% earnings growth, these metrics solidify its Netural investment rating.